Current Report Filing (8-k)
April 27 2021 - 5:27PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): April 22, 2021
Rennova
Health, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
001-35141
|
|
68-0370244
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
400
S. Australian Avenue, Suite 800, West Palm Beach,
Florida
|
|
33401
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(561)
855-1626
|
(Registrant’s
Telephone Number, Including Area Code)
|
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered under Section 12(b) of the Act:
Title of each
class
|
|
Trading Symbol
|
|
Name of each
exchange on which registered
|
None
|
|
None
|
|
None
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 8.01. Other Events
As
a result of conversions of shares of Series M Convertible Redeemable Preferred Stock and shares of Series N Convertible Redeemable
Preferred Stock of Rennova Health, Inc. (the “Company”), the Company currently has 5,587,901,679 shares of
common stock issued and outstanding. The Company is authorized to issue 10,000,000,000 shares of common stock. The Company expects
it will exhaust all of its authorized shares of common stock in the immediate future. It will not then be able to
issue additional shares of common stock unless and until it is able to amend its Certificate of Incorporation to increase
its authorized common stock or it effects a reverse split. The Company needs immediate additional capital to execute on its
business plan and without the ability to issue shares of common stock will have difficulty securing the capital required to continue
in business.
On
April 22, 2021, the Company entered into agreements with certain institutional investors for warrant prepayment promissory notes in the
aggregate principal amount of $220,000. The Company received proceeds of $200,000. All or any portion of the principal amount of these
notes may be applied, at the option of the payees, to the exercise price of any common stock purchase warrants held by the payees. The
notes are unsecured and mature in one year. They do not bear interest but an interest rate of 18% will be applied commencing five days
after any event of default that results in acceleration of the notes.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
April 27, 2021
|
RENNOVA
HEALTH, INC.
|
|
|
|
|
By:
|
/s/
Seamus Lagan
|
|
|
Seamus
Lagan
|
|
|
Chief
Executive Officer
|
|
|
(principal
executive officer)
|